Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma
Leon‐Ferre, Roberto A. , Kottschade, Lisa A. , Block, Matthew S. , Dronca, Roxana , Creagan, Edward T. , Allred, Jacob B., Lowe, Val J. , McWilliams, Robert R. , Markovic, Svetomir N.

Mayo Clinic

Melanoma Research | March 14, 2017 | Volume: 27 | Issue: 4 | Pages: 335-341

10.1097/cmr.0000000000000344 | PMID 28296712 Get It

The optimal surveillance for patients with resected high-risk melanoma is controversial. Select locoregional or oligometastatic recurrences can be cured with salvage resection. Data on the ability of PET/CT to detect such recurrences are sparse. We evaluated whether surveillance PET/CT in patients with resected stage III–IV melanoma led to detection of clinically occult recurrences amenable to curative-intent salvage treatment. We retrospectively identified 1429 melanoma patients who underwent PET/CT between January 2008 and October 2012 at Mayo Clinic (Rochester, Minnesota). A total of 1130 were excluded because of stage I–II, ocular or mucosal melanoma, incomplete resection, PET/CT not performed for surveillance or performed at a different institution, and records not available. A total of 299 patients were eligible. Overall, 162 (52%) patients developed recurrence [locoregional: 77 (48%), distant: 85 (52%)]. The first recurrence was clinically occult in 98 (60%) and clinically evident in 64 (40%). Clinically evident recurrences were more often superficial (skin, subcutaneous, or nodal) or in the brain, whereas clinically occult recurrences more often visceral. Overall, 90% of all recurrences were detected by 2.8 years. In all, 70% of patients with recurrence underwent curative-intent salvage treatment (locoregional: 94%, distant: 48%), with similar rates for clinically occult versus clinically evident recurrences (66 vs. 75%, P=0.240). Overall survival was superior among those who underwent curative-intent salvage treatment [5.9 vs. 1.2 years; hazard ratio=4.27, 95% confidence interval (CI)=2.68–6.80; P<0.001], despite 79% developing recurrence again. PET/CT had high sensitivity (88%, 95% CI=79.94–93.31%), specificity (90%, 95% CI=88.56–91.56%), and negative predictive value (99%, 95% CI=98.46–99.52%). However, the positive predictive value was only 37% (95% CI=31.32–43.68%). In patients with resected stage III–IV melanoma, surveillance PET/CT detected a large proportion of clinically occult recurrences amenable to curative-intent salvage treatment. Despite a high rate of second relapse, curative-intent salvage treatment was associated with superior overall survival. Even though PET/CT had high sensitivity, specificity, and negative predictive value, positive predictive value was poor, highlighting the need for histologic confirmation of PET/CT-detected abnormalities.
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue
Pham, Anthony , Jevremović, Dragan , Wiseman, Gregory A., Feldman, Andrew L. , Ristow, Kay M., Pham, Anthony Q, Broski, Stephen M. , Habermann, Thomas M. , Maurer, Matthew J. , Witzig, Thomas E. , Feldman, Andrew L , Jevremovic, Dragan

Mayo Clinic

Leukemia & Lymphoma | March 14, 2017 | Volume: 58 | Issue: 10 | Pages: 2342-2348

10.1080/10428194.2017.1300891 | PMID 28290723 Get It

Signaling pathways as therapeutic targets in biliary tract cancer
Yang, Jennifer , Farren, Matthew R. , Ahn, Daniel H. , Bekaii‐Saab, Tanios , Achilonu, Conrad Chibunna , Lesinski, Gregory B , Bekaii-Saab, Tanios S , Achilonu, Conrad C

Mayo Clinic

Expert Opinion on Therapeutic Targets | March 11, 2017 | Volume: 21 | Issue: 5 | Pages: 485-498

10.1080/14728222.2017.1306055 | PMID 28282502 Get It

Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes
Armasu, Sebastian M. , Kalli, Kimberly R., Heinzen, Ethan P. , Keeney, Gary L., Cliby, William A. , Oberg, Ann L. , Goode, Ellen L. , Kaufmann, Scott H. , Wang, Chen , Maurer, Matthew J.

Mayo Clinic

Clinical Cancer Research | March 9, 2017 | Volume: 23 | Issue: 15 | Pages: 4077-4085

10.1158/1078-0432.ccr-17-0246 | PMID 28280090 Get It

Abstract Purpose: Here we assess whether molecular subtyping identifies biological features of tumors that correlate with survival and surgical outcomes of high-grade serous ovarian cancer (HGSOC). Experimental Design: Consensus clustering of pooled mRNA expression data from over 2,000 HGSOC cases was used to define molecular subtypes of HGSOCs. This de novo classification scheme was then applied to 381 Mayo Clinic HGSOC patients with detailed survival and surgical outcome information. Results: Five molecular subtypes of HGSOC were identified. In the pooled dataset, three subtypes were largely concordant with prior studies describing proliferative, mesenchymal, and immunoreactive tumors (concordance &gt; 70%), and the group of tumors previously described as differentiated type was segregated into two new types, one of which (anti-mesenchymal) had downregulation of genes that were typically upregulated in the mesenchymal subtype. Molecular subtypes were significantly associated with overall survival (P &lt; 0.001) and with rate of optimal surgical debulking (≤1 cm, P = 1.9E−4) in the pooled dataset. Among stage III-C or IV Mayo Clinic patients, molecular subtypes were also significantly associated with overall survival (P = 0.001), as well as rate of complete surgical debulking (no residual disease; 16% in mesenchymal tumors compared with &gt;28% in other subtypes; P = 0.02). Conclusions: HGSOC tumors may be categorized into five molecular subtypes that associate with overall survival and the extent of residual disease following debulking surgery. Because mesenchymal tumors may have features that were associated with less favorable surgical outcome, molecular subtyping may have future utility in guiding neoadjuvant treatment decisions for women with HGSOC. Clin Cancer Res; 23(15); 4077–85. ©2017 AACR.
Use of High-Fidelity Simulation to Enhance Interdisciplinary Collaboration and Reduce Patient Falls
Bursiek, April A., Hopkins, Matthew R. , Breitkopf, Daniel M. , Grubbs, Pamela L., Joswiak, M. Ellen , Klipfel, Janee M., Johnson, Kristine M.

Mayo Clinic

Journal of Patient Safety | March 8, 2017 | Volume: 16 | Issue: 3 | Pages: 245-250

10.1097/pts.0000000000000277 | PMID 28272294 Get It

Objectives This pilot study aimed to determine the effect of nurse/physician interdisciplinary team training on patient falls. Specifically, we evaluated team training in a simulation center as a method for targeting and minimizing breakdowns in perceptions of respect, collaboration, communication, and role misunderstanding behaviors between care disciplines. Methods Registered nurses (RNs) were randomly assigned to participate. Residents were divided into groups and assigned based on their availability and clinical responsibility. All participants completed a demographic form, the Professional Practice Environment Assessment Scale (PPEAS), and the Mayo High Performance Teamwork Scale (MHPTS) after consenting and before participation in simulation training. The PPEAS and the MHPTS were readministered at 2 and 6 months after the simulation experience. Differences in MHPTS and PPEAS scores between the baseline and 2- and 6-month assessments were analyzed; fall rates over time were evaluated using Cochran-Armitage trend tests. Results After the team training exercises, teamwork as measured by the MHPTS improved significantly at both 2 and 6 months (P = 0.01; P < 0.001) compared with baseline measurement. Practice environment subscores, with the exception of positive organizational characteristics, also increased when measured 6 months after training. The primary outcome, reduction in anticipated patient falls, improved significantly (P = 0.02) over the course of the study. Conclusions Results of this pilot study show that team training exercises result in improvement in both patient safety (anticipated patient falls) and team member perception of their work environment. If validated by other studies, improvement in this patient safety metric would represent an important benefit of simulation and team training.
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Cynthia, X. , Northfelt, Donald W. , Forero, Andres , Anderson, Karen S. , Margenthaler, Julie A. , Aft, Rebecca , Hobday, Timothy J. , Moynihan, Timothy J. , Gillanders, William E. , Cyr, Amy, Eberlein, Timothy J. , Guo, Zhanfang , Lee, Michelle V. , Spies, Nicholas C. , Skidmore, Zachary L. , Griffith, Obi L. , Griffith, Malachi , Thomas, Shana , Bumb, Caroline, Bartlett, Cynthia Huang , Koehler, María , Al‐Kateb, Hussam , Sanati, Souzan , Hobday, Timothy, Moynihan, Timothy, Hieken, Tina, Gao, Feng , Luo, Jingqin , Goetz, Matthew P. , Hoog, Jeremy , Naughton, Michael J. , Ademuyiwa, Foluso O. , Suresh, Rama , Hieken, Tina J. , Krontiras, Helen , Vij, Kiran R , Ellis, Matthew J. , Griffith, Malachi , Griffith, Obi L

Mayo Clinic

Clinical Cancer Research | March 7, 2017 | Volume: 23 | Issue: 15 | Pages: 4055-4065

10.1158/1078-0432.ccr-16-3206 | PMID 28270497 Get It

Abstract Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the antiproliferative activity of the CDK4/6 inhibitor palbociclib in primary breast cancer as a prelude to adjuvant studies. Experimental Design: Eligible patients with clinical stage II/III ER+/HER2− breast cancer received anastrozole 1 mg daily for 4 weeks (cycle 0; with goserelin if premenopausal), followed by adding palbociclib (125 mg daily on days 1–21) on cycle 1 day 1 (C1D1) for four 28-day cycles unless C1D15 Ki67 &gt; 10%, in which case patients went off study due to inadequate response. Anastrozole was continued until surgery, which occurred 3 to 5 weeks after palbociclib exposure. Later patients received additional 10 to 12 days of palbociclib (Cycle 5) immediately before surgery. Serial biopsies at baseline, C1D1, C1D15, and surgery were analyzed for Ki67, gene expression, and mutation profiles. The primary endpoint was complete cell cycle arrest (CCCA: central Ki67 ≤ 2.7%). Results: Fifty patients enrolled. The CCCA rate was significantly higher after adding palbociclib to anastrozole (C1D15 87% vs. C1D1 26%, P &lt; 0.001). Palbociclib enhanced cell-cycle control over anastrozole monotherapy regardless of luminal subtype (A vs. B) and PIK3CA status with activity observed across a broad range of clinicopathologic and mutation profiles. Ki67 recovery at surgery following palbociclib washout was suppressed by cycle 5 palbociclib. Resistance was associated with nonluminal subtypes and persistent E2F-target gene expression. Conclusions: Palbociclib is an active antiproliferative agent for early-stage breast cancer resistant to anastrozole; however, prolonged administration may be necessary to maintain its effect. Clin Cancer Res; 23(15); 4055–65. ©2017 AACR.
Epidemiology and Impact of Abdominal Oblique Injuries in Major and Minor League Baseball
Conte, Stan, Cohen, Steven B. , Thompson, Matthew M., Angelo, John D’, Nguyen, Joseph , Camp, Christopher L. , Dines, Joshua S.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 7, 2017 | Volume: 5 | Issue: 3 | Pages: No page available

10.1177/2325967117694025 | PMID 28451598 Get It

Background: Oblique injuries are known to be a common cause of time out of play for professional baseball players, and prior work has suggested that injury rates may be on the rise in Major League Baseball (MLB). Purpose: To better understand the current incidence of oblique injuries, determine their impact based on time out of play, and to identify common injury patterns that may guide future injury prevention programs. Study Design: Descriptive epidemiological study. Methods: Using the MLB Health and Injury Tracking System, all oblique injuries that resulted in time out of play in MLB and Minor League Baseball (MiLB) during the 2011 to 2015 seasons were identified. Player demographics such as age, position/role, and handedness were included. Injury-specific factors analyzed included the following: date of injury, timing during season, days missed, mechanism, side, treatment, and reinjury status. Results: A total of 996 oblique injuries occurred in 259 (26%) MLB and 737 (74%) MiLB players. Although the injury rate was steady in MiLB, the MLB injury rate declined ( P = .037). A total of 22,064 days were missed at a mean rate of 4413 days per season and 22.2 days per injury. The majority of these occurred during batting (n = 455, 46%) or pitching (n = 348, 35%), with pitchers losing 5 days more per injury than batters ( P < .001). The leading side was injured in 77% of cases and took 5 days longer to recover from than trailing side injuries ( P = .009). Seventy-nine (7.9%) players received either a corticosteroid or platelet-rich plasma injection, and the mean recovery time was 11 days longer compared with those who did not receive an injection ( P < .001). Conclusion: Although the rate of abdominal oblique injuries is on the decline in MLB, this is not the case for MiLB, and these injuries continue to represent a significant source of time out of play in professional baseball. The vast majority of injuries occur on the lead side, and these injuries result in the greatest amount time out of play. The benefit of injections for the treatment of oblique injuries remains unknown.
Perforin Expression by CD8 T Cells Is Sufficient To Cause Fatal Brain Edema during Experimental Cerebral Malaria
Huggins, Matthew A. , Johnson, Holly L. , N’Songo, Aurelie, Hanson, Lisa , LaFrance, Stephanie J., Butler, Noah S. , Harty, John T. , Johnson, Aaron J. , Hanson, Lisa M, Jin, Fang , Johnson, Aaron J.

Mayo Clinic

Infection and Immunity | March 7, 2017 | Volume: 85 | Issue: 5 | Pages: No page available

10.1128/iai.00985-16 | PMID 28264905 Get It

ABSTRACTHuman cerebral malaria (HCM) is a serious complication ofPlasmodium falciparuminfection. The most severe outcomes for patients include coma, permanent neurological deficits, and death. Recently, a large-scale magnetic resonance imaging (MRI) study in humans identified brain swelling as the most prominent predictor of fatal HCM. Therefore, in this study, we sought to define the mechanism controlling brain edema through the use of the murine experimental cerebral malaria (ECM) model. Specifically, we investigated the ability of CD8 T cells to initiate brain edema during ECM. We determined that areas of blood-brain barrier (BBB) permeability colocalized with a reduction of the cerebral endothelial cell tight-junction proteins claudin-5 and occludin. Furthermore, through small-animal MRI, we analyzed edema and vascular leakage. Using gadolinium-enhanced T1-weighted MRI, we determined that vascular permeability is not homogeneous but rather confined to specific regions of the brain. Our findings show that BBB permeability was localized within the brainstem, olfactory bulb, and lateral ventricle. Concurrently with the initiation of vascular permeability, T2-weighted MRI revealed edema and brain swelling. Importantly, ablation of the cytolytic effector molecule perforin fully protected against vascular permeability and edema. Furthermore, perforin production specifically by CD8 T cells was required to cause fatal edema during ECM. We propose that CD8 T cells initiate BBB breakdown through perforin-mediated disruption of tight junctions. In turn, leakage from the vasculature into the parenchyma causes brain swelling and edema. This results in a breakdown of homeostatic maintenance that likely contributes to ECM pathology.
Microsurgery for Recurrent Vestibular Schwannoma after Previous Gross Total Resection
Perry, Avital , Graffeo, Christopher S. , III, William, Carlson, Matthew L. , Neff, Brian, Driscoll, Colin L. W., Driscoll, Michael J. , Neff, Brian A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 3, 2017 | Volume: 78 | Issue: S 01 | Pages: S1-S156

10.1055/s-0037-1600885 Get It

Macrophage Density Predicts Facial Nerve Outcome and Tumor Growth after Subtotal Resection of Vestibular Schwannoma
Graffeo, Christopher S. , Perry, Avital , Jentoft, Mark E. , Driscoll, Colin L. W., Neff, Brian, Carlson, Matthew L. , Jacob, Jeffrey T. , Link, Michael J. , Raghunathan, Aditya , Neff, Brian A., Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 3, 2017 | Volume: 78 | Issue: S 01 | Pages: S1-S156

10.1055/s-0037-1600614 Get It